An update on recent patents on thrombin inhibitors (2010 – 2013)

Bibliography

• Chan AK, Paredes N. The coagulation system in humans. Methods Mol Biol 2013;992:3-12
   PubMedGoogle Scholar
• Mackman N. Triggers, targets and treatments for thrombosis. Nature 2008;451:914-18
   PubMed Web of Science ®Google Scholar
• Wardrop D, Keeling D. The story of the discovery of heparin and warfarin. Br J Haematol 2008;141:757-63
   PubMed Web of Science ®Google Scholar
• Francis CW. Warfarin: an historical perspective. Hematology Am Soc 2008:251. doi: 10.1182/asheducation-2008.1.251.
   Google Scholar
• Henry BL, Desai UR. Anticoagulants. In: Abraham DJ, Rotella DP, editors. Burger's medicinal chemistry, drug discovery and development. 7th edition. John Wiley; Hoboken, NJ: 2010. p. 365-408
   Google Scholar
• Ansell J, Hirsh J, Hylek E, et al. Pharmacology and management of the vitamin K antagonists: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th edition). Chest 2008;133:160S-98S
   PubMed Web of Science ®Google Scholar
• Di Nisio M, Middeldorp S, Buller HR. Direct thrombin inhibitors. N Engl J Med 2005;353:1028-40
   PubMed Web of Science ®Google Scholar
• Akwaa F, Spyropoulos AC. Novel oral anticoagulants: a review of the literature and considerations in special clinical situations. Hosp Pract 2013;41:8-18
   Google Scholar
• Green D. Coagulation cascade. Hemodial Int 2006;10(Suppl 2):S2-4
   Google Scholar
• Davie EW, Fujikawa K, Kisiel W. The coagulation cascade: initiation, maintenance, and regulation. Biochemistry 1991;30:10363-70
   PubMed Web of Science ®Google Scholar
• Laki K, Gladner JA. Chemistry and physiology of the fibrinogen-fibrin transition. Physiol Rev 1964;44:127-60
   PubMed Web of Science ®Google Scholar
• Versteeg HH, Heemskerk JW, Levi M, et al. New fundamentals in hemostasis. Physiol Rev 2013;93:327-58
   PubMed Web of Science ®Google Scholar
• von dem Borne PA, Meijers JC, Bouma BN. Feedback activation of factor XI by thrombin in plasma results in additional formation of thrombin that protects fibrin clots from fibrinolysis. Blood 1995;86:3035-42
   PubMed Web of Science ®Google Scholar
• De Candia E, Hall SW, Rutella S, et al. Binding of thrombin to glycoprotein Ib accelerates the hydrolysis of PAR-1 on intact platelets. J Biol Chem 2001;276:4692-8
   PubMed Web of Science ®Google Scholar
• Esmon CT. The roles of protein C and thrombomodulin in the regulation of blood coagulation. J Biol Chem 1989;264:4743-6
   PubMed Web of Science ®Google Scholar
• Olson ST, Bjork I. Regulation of thrombin activity by antithrombin and heparin. Semin Thromb Hemost 1994;20:373-409
   PubMed Web of Science ®Google Scholar
• Kraut J. Serine proteases: structure and mechanism of catalysis. Annu Rev Biochem 1977;46:331-58
   PubMed Web of Science ®Google Scholar
• Bode W, Mayr I, Baumann U, et al. The refined 1.9 a crystal-structure of human alpha-thrombin - interaction with D-Phe-Pro-Arg chloromethylketone and significance of the Tyr-Pro-Pro-Trp insertion segment. Embo J 1989;8:3467-75
   PubMed Web of Science ®Google Scholar
• Di Cera E, Guinto ER, Vindigni A, et al. The Na+ binding site of thrombin. J Biol Chem 1995;270:22089-92
   PubMedGoogle Scholar
• Abrahams JP, Thomassen EA. Mechanism of thrombin's enigmatic sodium switch revealed. Structure 2003;11:363-4
   PubMedGoogle Scholar
• Huntington JA, Esmon CT. The molecular basis of thrombin allostery revealed by a 1.8 A structure of the "slow" form. Structure 2003;11:469-79
   PubMedGoogle Scholar
• Huntington JA. Thrombin plasticity. Biochim Biophys Acta 2012;1824:246-52
   PubMedGoogle Scholar
• Guillin MC, Bezeaud A, Bouton MC, et al. Thrombin specificity. Thromb Haemost 1995;74:129-33
   PubMedGoogle Scholar
• Lechtenberg BC, Johnson DJ, Freund SM, et al. NMR resonance assignments of thrombin reveal the conformational and dynamic effects of ligation. Proc Natl Acad Sc USA 2010;107:14087-92
   PubMedGoogle Scholar
• Lechtenberg BC, Freund SM, Huntington JA. An ensemble view of thrombin allostery. Biol Chem 2012;393:889-98
   PubMed Web of Science ®Google Scholar
• Qureshi SH, Yang L, Manithody C, et al. Mutagenesis studies toward understanding allostery in thrombin. Biochemistry 2009;48:8261-70
   PubMedGoogle Scholar
• Gandhi PS, Chen Z, Mathews FS, et al. Structural identification of the pathway of long-range communication in an allosteric enzyme. Proc Natl Acad Sc USA 2008;105:1832-7
   PubMedGoogle Scholar
• Di Cera E, Page MJ, Bah A, et al. Thrombin allostery. Phys Chem Chem Phys 2007;9:1291-306
   PubMedGoogle Scholar
• Malovichko MV, Sabo TM, Maurer MC. Ligand binding to anion-binding exosites regulates conformational properties of thrombin. J Biol Chem 2013;288:8667-78
   PubMed Web of Science ®Google Scholar
• Keisu M, Andersson TB. Drug-induced liver injury in humans: the case of ximelagatran. Handb Exp Pharmacol 2010;196:407-18
   PubMedGoogle Scholar
• Miller JL. Argatroban approved for heparin-induced thrombocytopenia. Am J Health Syst Pharm 2000;57:1650
   PubMedGoogle Scholar
• Ahmed S, Levin V, Malacoff R, et al. Dabigatran: a new chapter in anticoagulation. Cardiovasc Hematol Agents Med Chem 2012;10:116-23
   PubMedGoogle Scholar
• Sixma JJ, de Groot PG. The ideal anti-thrombotic drug. Thromb Res 1992;68:507-12
   PubMedGoogle Scholar
• Heidbuchel H, Verhamme P, Alings M, et al. EHRA Practical Guide on the use of new oral anticoagulants in patients with non-valvular atrial fibrillation: executive summary. Eur Heart J 2013;34:2094-106
   PubMed Web of Science ®Google Scholar
• Southworth MR, Reichman ME, Unger EF. Dabigatran and postmarketing reports of bleeding. N Engl J Med 2013;368:1272-4
   PubMed Web of Science ®Google Scholar
• Attia JR, Pearce R. The use, misuse and abuse of dabigatran. Med J Aust 2013;198:356-7
   PubMedGoogle Scholar
• Maddry JK, Amir MK, Sessions D, et al. Fatal dabigatran toxicity secondary to acute renal failure. Am J Emerg Med 2013;31:462; e1-2
   PubMedGoogle Scholar
• Fountzilas C, George J, Levine R. Dabigatran overdose secondary to acute kidney injury and amiodarone use. NZ Med J 2013;126:110-12
   PubMedGoogle Scholar
• Shanghai Inst. Pharm. Industry. Peptide compound and preparation method and application thereof. CN101724016; 2010
   Google Scholar
• Shanghai Inst. Pharm. Industry. Prolinamide derivative as thrombin inhibitor, preparation method and application thereof. WO2012062187; 2012
   Google Scholar
• Bajusz S, Szell E, Bagdy D, et al. Highly active and selective anticoagulants: D-Phe-Pro-Arg-H, a free tripeptide aldehyde prone to spontaneous inactivation, and its stable N-methyl derivative, D-MePhe-Pro-Arg-H. J Med Chem 1990;33:1729-35
   PubMed Web of Science ®Google Scholar
• Brighton TA. The direct thrombin inhibitor melagatran/ximelagatran. Med J Aust 2004;181:432-7
   PubMedGoogle Scholar
• Ahrens I, Peter K, Lip GY, et al. Development and clinical applications of novel oral anticoagulants. Part II. Drugs under clinical investigation. Discov Med 2012;13:445-50
   PubMed Web of Science ®Google Scholar
• Atrial fibrillation (AF) patients not taking vitamin-K antagonists (VKA). ClinicalTrials.gov NIH Available from: http://clinicaltrials.gov/show/NCT00623779 [Last accessed 6 September 2013]
   Google Scholar
• Prevention of stroke and systemic embolic events in patients with atrial fibrillation. ClinicalTrials.gov NIH. Available from: http://clinicaltrials.gov/show/NCT00684307 [Last accessed 6 September 2013]
   Google Scholar
• Deinum J, Mattsson C, Inghardt T, et al. Biochemical and pharmacological effects of the direct thrombin inhibitor AR-H067637. Thromb Haemost 2009;101:1051-9
   PubMed Web of Science ®Google Scholar
• Johansson S, Cullberg M, Eriksson UG, et al. Single-dose pharmacokinetics, pharmacodynamics and safety of AZD0837, a novel oral direct thrombin inhibitor, in young healthy male subjects. Int J Clin Pharmacol Ther 2011;49:258-67
   PubMed Web of Science ®Google Scholar
• Lip GY, Rasmussen LH, Olsson SB, et al. Oral direct thrombin inhibitor AZD0837 for the prevention of stroke and systemic embolism in patients with non-valvular atrial fibrillation: a randomized dose-guiding, safety, and tolerability study of four doses of AZD0837 vs. vitamin K antagonists. Eur Heart J 2009;30:2897-907
   PubMed Web of Science ®Google Scholar
• Lip GY, Rasmussen LH, Olsson SB, et al. Oral direct thrombin inhibitor AZD0837 for the prevention of stroke and systemic embolism in patients with non-valvular atrial fibrillation: a Phase II study of AZD0837 in patients who are appropriate for but unable or unwilling to take vitamin K antagonist therapy. Thromb Res 2011;127:91-9
   PubMed Web of Science ®Google Scholar
• Pharmacokinetics of extended-release test- and reference formulations of AZD0837. ClinicalTrials.gov NIH. Available from: http://clinicaltrials.gov/show/NCT00878618 [Last accessed 6 September 2013]
   Google Scholar
• Tianjin Jiahong Technology LLC. Aromatic amidine derivatives, and preparation method and pharmaceutical application thereof. CN102827053; 2012
   Google Scholar
• Riester D, Wirsching F, Salinas G, et al. Thrombin inhibitors identified by computer-assisted multiparameter design. Proc Natl Acad Sci USA 2005;102:8597-602
   PubMedGoogle Scholar
• Matrix Pharma, Inc. Thrombin inhibiting compositions. WO2011120040A2; 2011
   Google Scholar
• Friedrich R, Riester D, Gottig P, et al. Structure of a novel thrombin inhibitor with an uncharged D-amino acid as P1 residue. Eur J Med Chem 2008;43:1330-5
   PubMedGoogle Scholar
• Rocha ESM, Beraldo WT, Rosenfeld G. Bradykinin, a hypotensive and smooth muscle stimulating factor released from plasma globulin by snake venoms and by trypsin. Am J Physiol 1949;156:261-73
   PubMed Web of Science ®Google Scholar
• Meloni FJ, Schmaier AH. Low molecular weight kininogen binds to platelets to modulate thrombin-induced platelet activation. J Biol Chem 1991;266:6786-94
   PubMed Web of Science ®Google Scholar
• Cleary DB, Ehringer WD, Maurer MC. Establishing the inhibitory effects of bradykinin on thrombin. Arch Biochem Biophys 2003;410:96-106
   PubMedGoogle Scholar
• The Regents of the University of Michigan. Synthetic peptide inhibitors of thrombin and thrombin activation of protease activated receptors 1 and 4. US7879792B2; 2011
   Google Scholar
• Nieman MT, Burke F, Warnock M, et al. Thrombostatin FM compounds: direct thrombin inhibitors - mechanism of action in vitro and in vivo. J Thromb Haemost 2008;6:837-45
   PubMedGoogle Scholar
• Cheng-Lai A. Cardiovascular drug highlight: hirudin. Heart Dis 1999;1:41-9
   PubMedGoogle Scholar
• Koh CY, Kazimirova M, Trimnell A, et al. Variegin, a novel fast and tight binding thrombin inhibitor from the tropical bont tick. J Biol Chem 2007;282:29101-13
   PubMed Web of Science ®Google Scholar
• Natural Environment Research Council. Method of modifying serine protease inhibitors. WO2010128285A2; 2010
   Google Scholar
• Koh CY, Kumar S, Kazimirova M, et al. Crystal structure of thrombin in complex with S-variegin: insights of a novel mechanism of inhibition and design of tunable thrombin inhibitors. PLoS One 2011;6:e26367
   Google Scholar
• Stangier J, Stahle H, Rathgen K, et al. Pharmacokinetics and pharmacodynamics of dabigatran etexilate, an oral direct thrombin inhibitor, are not affected by moderate hepatic impairment. J Clin Pharmacol 2008;48:1411-19
   PubMed Web of Science ®Google Scholar
• Hauel NH, Nar H, Priepke H, et al. Structure-based design of novel potent nonpeptide thrombin inhibitors. J Med Chem 2002;45:1757-66
   PubMed Web of Science ®Google Scholar
• Stangier J, Rathgen K, Stahle H, et al. The pharmacokinetics, pharmacodynamics and tolerability of dabigatran etexilate, a new oral direct thrombin inhibitor, in healthy male subjects. Br J Clin Pharmacol 2007;64:292-303
   PubMed Web of Science ®Google Scholar
• Eisert WG, Hauel N, Stangier J, et al. Dabigatran: an oral novel potent reversible nonpeptide inhibitor of thrombin. Arterioscler Thromb Vasc Biol 2010;30:1885-9
   PubMed Web of Science ®Google Scholar
• Beijing Meibeita Pharmaceutical Res. Inst. Co. Ltd. Dabigatran ester derivatives as prodrug. CN102050815; 2011
   Google Scholar
• Beijing Meibeita Pharmaceutical Res. Inst. Co. Ltd. Ester derivatives of dabigatran. CN102050814; 2011
   Google Scholar
• Beijing Prelude Pharm. Tech. Co. Ltd. Dabigatran etexilate derivative and preparation method and application thereof. CN102766134; 2012
   Google Scholar
• Tianjin Inst. Pharm. Res. Dabigatran derivatives and preparation method thereof. CN102875529; 2013
   Google Scholar
• Tianjin Institute of Pharmaceutical Research. Preparation, method and application of dabigatran ester derivatives. CN102993175; 2013
   Google Scholar
• Tianjin Institute of Pharmaceutical Research. Dabigatran ester derivatives as pro-drug. CN102993174; 2013
   Google Scholar
• Suzhou Borui Pharmaceuticals, Inc. (benzimidazole-2-yl)pyridine derivative and application thereof to preparation of anticoagulant medicines. CN102649787; 2012
   Google Scholar
• Hefei Yigong Medicin Co. Ltd, Univ. China. Pharm. Oral thrombin inhibitor and preparation method and medical use thereof. WO2012174856; 2012
   Google Scholar
• Tsai CC, Lai TY, Huang WC, et al. Inhibitory effects of potassium channel blockers on tetramethylpyrazine-induced relaxation of rat aortic strip in vitro. Life Sci 2002;71:1321-30
   PubMedGoogle Scholar
• Zhu XL, Xiong LZ, Wang Q, et al. Therapeutic time window and mechanism of tetramethylpyrazine on transient focal cerebral ischemia/reperfusion injury in rats. Neurosci Lett 2009;449:24-7
   PubMed Web of Science ®Google Scholar
• Li M, Handa S, Ikeda Y, et al. Specific inhibiting characteristics of tetramethylpyrazine, one of the active ingredients of the Chinese herbal medicine 'Chuanxiong,' on platelet thrombus formation under high shear rates. Thromb Res 2001;104:15-28
   PubMed Web of Science ®Google Scholar
• Angelico M, Carli L, Piat C, et al. Effects of isosorbide-5-mononitrate compared with propranolol on first bleeding and long-term survival in cirrhosis. Gastroenterology 1997;113:1632-9
   PubMed Web of Science ®Google Scholar
• Univ. China Pharma. Nitric oxide donor with thrombin inhibition effect, as well as preparation method and medical application thereof. CN102633780; 2012
   Google Scholar
• Univ. China Pharma. Non-peptide thrombin inhibitors as well as preparation method and medical application thereof. CN102250099; 2011
   Google Scholar
• Univ. Fudan. Thrombase inhibitor containing guanidyl heterocyclic compound and preparation method thereof. CN101665465; 2010
   Google Scholar
• Xu X, Song F, Wang S, et al. Dibenzyl bromophenols with diverse dimerization patterns from the brown alga Leathesia nana. J Nat Prod 2004;67:1661-6
   PubMed Web of Science ®Google Scholar
• Inst. of Oceanology of Chinese Acadmey of Science. Chemical complete synthesis method of medicine used for treating thrombus heart cerebrovascular disease. CN102020621; 2011
   Google Scholar
• Shi D LX, Li J, Guo S, et al. Antithrombotic effects of bromophenol, an alga-derived thrombin inhibitor. Chin J Oceanology Limnol 2010;28:96-8
   Google Scholar
• Guo S LJ, Li T, Shi D, Han L. Synthesis of three bromophenols from red algae as PTP1B inhibitors. Clin J Oceanol Limnol 2011;29:68-74
   Google Scholar
• Shi D, Li J, Jiang B, et al. Bromophenols as inhibitors of protein tyrosine phosphatase 1B with antidiabetic properties. Bioorg Med Chem Lett 2012;22:2827-32
   PubMedGoogle Scholar
• Shi DY, Li J, Guo SJ, et al. The antitumor effect of bromophenol derivatives in vitro and Leathesia nana extract in vivo. Chin J Oceanology Limnol 2009;27:277-82
   Web of Science ®Google Scholar
• Illig C, Eisennagel S, Bone R, et al. Expanding the envelope of structure-based drug design using chemical libraries: application to small-molecule inhibitors of thrombin. Med Chem Res 1998;8:244-60
   Web of Science ®Google Scholar
• Lu TB, Tomczuk B, Illig CR, et al. In vitro evaluation and crystallographic analysis of a new class of selective, non-amide-based thrombin inhibitors. Bioorg Med Chem Lett 1998;8:1595-600
   PubMed Web of Science ®Google Scholar
• Soll RM, Lu T, Tomczuk B, et al. Amidinohydrazones as guanidine bioisosteres: application to a new class of potent, selective and orally bioavailable, non-amide-based small-molecule thrombin inhibitors. Bioorg Med Chem Lett 2000;10:1-4
   PubMedGoogle Scholar
• Lu TB, Soll RM, Illig CR, et al. Structure-activity and crystallographic analysis of a new class of non-amide-based thrombin inhibitor. Bioorg Med Chem Lett 2000;10:79-82
   PubMedGoogle Scholar
• Lu TB, Tomczuk B, Bone R, et al. Non-peptidic phenyl-based thrombin inhibitors: exploring structural requirements of the S1 specificity pocket with amidines. Bioorg Med Chem Lett 2000;10:83-5
   PubMedGoogle Scholar
• Tomczuk B, Lu TB, Soll RM, et al. Oxyguanidines: application to non-peptidic phenyl-based thrombin inhibitors. Bioorg Med Chem Lett 2003;13:1495-8
   PubMedGoogle Scholar
• Lu TB, Markotan T, Coppo F, et al. Oxyguanidines. Part 2: discovery of a novel orally active thrombin inhibitor through structure-based drug design and parallel synthesis. Bioorg Med Chem Lett 2004;14:3727-31
   PubMedGoogle Scholar
• Bionika LLC. Thrombin function compounds and pharmaceutical compositions based on them. US20100324058A1; 2010
   Google Scholar
• Sinauridze EI, Romanov AN, Gribkova IV, et al. New synthetic thrombin inhibitors: molecular design and experimental verification. PLoS One 2011;6(5):e19969
   Google Scholar
• Stefanadis C, Diamantopoulos L, Vlachopoulos C, et al. Thermal heterogeneity within human atherosclerotic coronary arteries detected in vivo: a new method of detection by application of a special thermography catheter. Circulation 1999;99:1965-71
   PubMed Web of Science ®Google Scholar
• Madjid M, Naghavi M, Malik BA, et al. Thermal detection of vulnerable plaque. Am J Cardiol 2002;90:36L-9L
   PubMed Web of Science ®Google Scholar
• National Research Council of Canada. Locally-active anticoagulants and anti-inflammatory agents. WO2012142696A1; 2012
   Google Scholar
• Cochran AG, Skelton NJ, Starovasnik MA. Tryptophan zippers: stable, monomeric beta -hairpins. Proc Natl Acad Sci USA 2001;98:5578-83
   PubMed Web of Science ®Google Scholar
• Buijsman RC, Basten JE, van Dinther TG, et al. Design and synthesis of a novel synthetic NAPAP-penta-saccharide conjugate displaying a dual antithrombotic action. Bioorg Med Chem Lett 1999;9:2013-18
   PubMedGoogle Scholar
• Akzo Nobel, Universiteit Liden. Antithrombotic compounds. WO9965934; 1999
   Google Scholar
• Endotis Pharma. Oligosaccharide conjugates in the prevention of ischemia-reperfusion injury. WO2012146774; 2012
   Google Scholar
• Olson ST, Swanson R, Petitou M. Specificity and selectivity profile of EP217609: a new neutralizable dual-action anticoagulant that targets thrombin and factor Xa. Blood 2012;119:2187-95
   PubMed Web of Science ®Google Scholar
• Petitou M, Nancy-Portebois V, Dubreucq G, et al. From heparin to EP217609: the long way to a new pentasaccharide-based neutralisable anticoagulant with an unprecedented pharmacological profile. Thromb Haemost 2009;102:804-10
   PubMed Web of Science ®Google Scholar
• Gueret P, Krezel C, Van Giersbergen PLM, et al. First human study with EP217609, a new synthetic parenteral neutralizable dual action anticoagulant. 21st International Congress of Thrombosis; Milan, Italy; 2010
   Google Scholar
• Endotis Pharma. Combination of an anticoagulant and avidin useful in surgical intervention and clinical procedure. WO2013007762; 2013
   Google Scholar
• Verseon Corp. Multisubstituted aromatic compounds as inhibitors of thrombin. WO2011126903A2; 2011
   Google Scholar
• Verseon Corp. Dual inhibitor compounds and methods of use thereof. WO2013049591A2; 2013
   Google Scholar
• Musumeci D, Montesarchio D. Polyvalent nucleic acid aptamers and modulation of their activity: a focus on the thrombin binding aptamer. Pharmacol Ther 2012;136:202-15
   PubMed Web of Science ®Google Scholar
• Bock LC, Griffin LC, Latham JA, et al. Selection of single-stranded DNA molecules that bind and inhibit human thrombin. Nature 1992;355:564-6
   PubMed Web of Science ®Google Scholar
• Wu Q, Tsiang M, Sadler JE. Localization of the single-stranded DNA binding site in the thrombin anion-binding exosite. J Biol Chem 1992;267:24408-12
   PubMedGoogle Scholar
• Paborsky LR, McCurdy SN, Griffin LC, et al. The single-stranded DNA aptamer-binding site of human thrombin. J Biol Chem 1993;268:20808-11
   PubMed Web of Science ®Google Scholar
• Macaya RF, Schultze P, Smith FW, et al. Thrombin-binding DNA aptamer forms a unimolecular quadruplex structure in solution. Proc Natl Acad Sci USA 1993;90:3745-9
   PubMed Web of Science ®Google Scholar
• Padmanabhan K, Padmanabhan KP, Ferrara JD, et al. The structure of alpha-thrombin inhibited by a 15-mer single-stranded DNA aptamer. J Biol Chem 1993;268:17651-4
   PubMed Web of Science ®Google Scholar
• Padmanabhan K, Tulinsky A. An ambiguous structure of a DNA 15-mer thrombin complex. Acta Crystallogr D, Biol Crystallogr 1996;52:272-82
   PubMedGoogle Scholar
• Wang KY, McCurdy S, Shea RG, et al. A DNA aptamer which binds to and inhibits thrombin exhibits a new structural motif for DNA. Biochemistry 1993;32:1899-904
   PubMed Web of Science ®Google Scholar
• Schultze P, Macaya RF, Feigon J. Three-dimensional solution structure of the thrombin-binding DNA aptamer d(GGTTGGTGTGGTTGG). J Mol Biol 1994;235:1532-47
   PubMed Web of Science ®Google Scholar
• Kelly JA, Feigon J, Yeates TO. Reconciliation of the X-ray and NMR structures of the thrombin-binding aptamer d(GGTTGGTGTGGTTGG). J Mol Biol 1996;256:417-22
   PubMed Web of Science ®Google Scholar
• Avino A, Fabrega C, Tintore M, et al. Thrombin binding aptamer, more than a simple aptamer: chemically modified derivatives and biomedical applications. Curr Pharm Des 2012;18:2036-47
   Google Scholar
• Diener JL, Wagner-Whyte J, Fontana D; Archemix Corp. Aptamers that bind thrombin with high affinity. WO2007025049; 2007
   Google Scholar
• Griffin LC, Tidmarsh GF, Bock LC, et al. In vivo anticoagulant properties of a novel nucleotide-based thrombin inhibitor and demonstration of regional anticoagulation in extracorporeal circuits. Blood 1993;81:3271-6
   PubMed Web of Science ®Google Scholar
• Apto-Farm. Anti-thrombosis aptamers and method for stabilizing the structure thereof. EP2514822A1; 2012
   Google Scholar
• Archemix Corp. Anti-thrombin aptamer formulations and methods for use. WO2010033167A2; 2010
   Google Scholar
• Study of NU172 as anticoagulation in patients undergoing off-pump CABG surgery (SNAP-CABG-OFF). ClinicalTrials.gov NIH Available from: http://clinicaltrials.gov/show/NCT00808964 [Last accessed 6 September 2013]
   Google Scholar
• Davin LB, Lewis NG. Lignin primary structures and dirigent sites. Curr Opin Biotechnol 2005;16:407-15
   PubMed Web of Science ®Google Scholar
• Virginia Commonwealth University. Cinnamic acid-based oligomers and uses thereof. US8491872B2; 2013
   Google Scholar
• Henry BL, Thakkar JN, Liang A, et al. Sulfated, low molecular weight lignins inhibit a select group of heparin-binding serine proteases. Biochem Biophys Res Commun 2012;417:382-6
   PubMed Web of Science ®Google Scholar
• Henry BL, Monien BH, Bock PE, et al. A novel allosteric pathway of thrombin inhibition: exosite II mediated potent inhibition of thrombin by chemo-enzymatic, sulfated dehydropolymers of 4-hydroxycinnamic acids. J Biol Chem 2007;282:31891-9
   PubMed Web of Science ®Google Scholar
• Monien BH, Henry BL, Raghuraman A, et al. Novel chemo-enzymatic oligomers of cinnamic acids as direct and indirect inhibitors of coagulation proteinases. Bioorg Med Chem 2006;14:7988-98
   PubMedGoogle Scholar
• Henry BL, Thakkar JN, Martin EJ, et al. Characterization of the plasma and blood anticoagulant potential of structurally and mechanistically novel oligomers of 4-hydroxycinnamic acids. Blood Coagul Fibrinolysis 2009;20:27-34
   PubMedGoogle Scholar
• Rawson TE, VanGorp KA, Yang J, et al. Separation of 21-(R)- and 21-(S)-argatroban: solubility and activity of the individual diastereoisomers. J Pharm Sci 1993;82:672-3
   PubMed Web of Science ®Google Scholar
• Argatroban injection solution. Available from: http://www.fda.gov/downloads/advisorycommittees/committeesmeetingmaterials/pediatricadvisorycommittee/ucm192057.pdf [Last accessed 10 July 2013]
   Google Scholar
• Tianjin Weijie Technology LLC. 21(R) argatroban intravenous injection with alcohol as solubilizer. CN102228426; 2011
   Google Scholar
• Baxter Healthcare. Argatroban formulation. US8034830B2; 2011
   Google Scholar
• Eagle Pharmaceuticals. Alcohol free formulation of argatroban. US20130023559A1; 2013
   Google Scholar
• Dorniani D, Hussein MZ, Kura AU, et al. Preparation of Fe3O4 magnetic nanoparticles coated with gallic acid for drug delivery. Int J Nanomedicine 2012;7:5745-56
   PubMed Web of Science ®Google Scholar
• Mok H, Zhang M. Superparamagnetic iron oxide nanoparticle-based delivery systems for biotherapeutics. Expert Opin Drug Deliv 2013;10:73-87
   PubMed Web of Science ®Google Scholar
• Jiangsu Yeming Biomedical Technology Ltd. Thrombin inhibitor SSR182289A magnetic nanometer microsphere and preparation method thereof. CN102614128; 2012
   Google Scholar
• Berry CN, Lassalle G, Lunven C, et al. SSR182289A, a novel, orally active thrombin inhibitor: in vitro profile and ex vivo anticoagulant activity. J Pharmacol Exp Ther 2002;303:1189-98
   PubMedGoogle Scholar
• Boehringer Ingelheim. Method for manufacturing medicinal compounds containing dabigatran. WO2010007016; 2010
   Google Scholar
• Boehringer Ingelheim. 3-[(2-{[4-(hexyloxycarbonylaminoiminomethyl)phenylamino]methyl}-1-methyl-1H-benzimidazol-5-carbonyl)pyridin-2-ylamino]propionic acid ethylester methansulfonate and its use as medicament. US20050234104A1; 2005
   Google Scholar
• ConjuChem, Inc. Antibodies to argatroban derivatives and their use in therapeutic and diagnostic treatments. US6440417; 2002
   Google Scholar
• Tianjin Weijie Technology Co. Ltd. Argatroban separation method. CN1951936; 2006
   Google Scholar
• Hainan Kangling Pharmaceuticals. Argatroban compound and preparation method thereof. CN102408468; 2012
   Google Scholar
• Boehringer Ingelheim Pharma. Disubstituted bicyclic heterocycles, their production and use as medicaments. WO9837075A1; 1998
   Google Scholar
• Esteve Quimica, S. A. Process of preparing a thrombin specific inhibitor. WO2012004396A2; 2012
   Google Scholar
• Zentiva K. S. A method for the preparation of dabigatran and its intermediates. WO2010045900A1; 2010
   Google Scholar
• Zentiva K. S. Method for the preparation of dabigatran. US8394961B1; 2013
   Google Scholar
• Boehringer Ingelheim. Process for the manufacture of dabigatran etexilate. US20130158270A1; 2013
   Google Scholar
• Merck & Co. Sanderson PE, Lyle TA, Dorsey BD. Pyrazinone thrombin inhibitors. WO9911267A1; 1999
   Google Scholar
• Burgey CS, Robinson KA, Lyle TA, et al. Metabolism-directed optimization of 3-aminopyrazinone acetamide thrombin inhibitors. Development of an orally bioavailable series containing P1 and P3 pyridines. J Med Chem 2003;46:461-73
   PubMed Web of Science ®Google Scholar
• Diakron Pharmaceuticals. Process for the preparation of pyrazinone thrombin inhibitor and its intermediates. US20110105753A1; 2010
   Google Scholar
• Verstraete M, Zoldhelyi P. Novel antithrombotic drugs in development. Drugs 1995;49:856-84
   PubMed Web of Science ®Google Scholar
• Deangelis PL, Liu J, Linhardt RJ. Chemoenzymatic synthesis of glycosaminoglycans: re-creating, re-modeling and re-designing nature's longest or most complex carbohydrate chains. Glycobiology 2013;23:764-77
   PubMed Web of Science ®Google Scholar
• King CS, Holley AB, Moores LK. Moving toward a more ideal anticoagulant: the oral direct thrombin and factor Xa inhibitors. Chest 2013;143:1106-16
   PubMedGoogle Scholar
• Roser-Jones C, Chan M, Howard EL, et al. Factor IXa as a target for pharmacologic inhibition in acute coronary syndrome. Cardiovasc Ther 2011;29:e22-35
   Google Scholar
• Schumacher WA, Luettgen JM, Quan ML, et al. Inhibition of factor XIa as a new approach to anticoagulation. Arterioscler Thromb Vasc Biol 2010;30:388-92
   PubMed Web of Science ®Google Scholar
• Howard EL, Becker KC, Rusconi CP, et al. Factor IXa inhibitors as novel anticoagulants. Arterioscler Thromb Vasc Biol 2007;27:722-7
   PubMed Web of Science ®Google Scholar
• Factor IX inhibition in thrombosis prevention (The FIXIT Trial). ClinicalTrials.gov NIH Available from: http://clinicaltrials.gov/show/NCT00119457 [Last accessed 6 September 2013]
   Google Scholar
• Al-Horani RA, Ponnusamy P, Mehta AY, et al. Sulfated pentagalloylglucoside is a potent, allosteric, and selective inhibitor of factor XIa. J Med Chem 2013;56:867-78
   PubMed Web of Science ®Google Scholar
• Wong PC, Crain EJ, Watson CA, et al. A small-molecule factor XIa inhibitor produces antithrombotic efficacy with minimal bleeding time prolongation in rabbits. J Thromb Thrombolysis 2011;32:129-37
   PubMed Web of Science ®Google Scholar
• Schumacher WA, Seiler SE, Steinbacher TE, et al. Antithrombotic and hemostatic effects of a small molecule factor XIa inhibitor in rats. Eur J Pharmacol 2007;570:167-74
   PubMed Web of Science ®Google Scholar